Changelog — 2026-02-12
2026-02-12
M
MRBK
Meridian Corp
Status: RECRUITING → TERMINATED (recruitment challenges) — NA
NCT06897618
• Na • Status: Recruiting → Terminated • Why stopped: recruitment challenges
🚩 MAJOR
2026-02-12
PFE
PFIZER INC
Status: COMPLETED → TERMINATED (Closed due to slow accrual) — PHASE2
NCT03913559
• Phase 2 • Status: Completed → Terminated • Why stopped: Closed due to slow accrual
🚩 MAJOR
2026-02-12
K
KPTI
Karyopharm Therapeutics Inc.
Study arms updated — PHASE2
NCT05980806
• Phase 2
HIGH
2026-02-12
NVS
NOVARTIS AG
Enrollment 50→22 (-56%) — PHASE2
NCT02934568
• Phase 2 • Enrollment 50→22 (-56%)
MEDIUM
2026-02-12
F
FDMT
4D Molecular Therapeutics, Inc.
Locations updated — PHASE3
NCT07064759
• Phase 3
MEDIUM
2026-02-12
F
FDMT
4D Molecular Therapeutics, Inc.
Enrollment 400→480 (20%) — PHASE3
NCT07064759
• Phase 3 • Enrollment 400→480 (+20%)
MEDIUM
2026-02-12
R
RXRX
RECURSION PHARMACEUTICALS, INC.
Enrollment 165→230 (39%) — PHASE1
NCT05985655
• Phase 1 • Enrollment 165→230 (+39%)
MEDIUM
2026-02-12
REGN
REGENERON PHARMACEUTICALS, INC.
Locations updated — PHASE2
NCT06465329
• Phase 2
MEDIUM
2026-02-12
NVS
NOVARTIS AG
Enrollment 46→47 (2%) — PHASE2
NCT05849298
• Phase 2 • Enrollment 46→47 (+2%)
MEDIUM
2026-02-12
A
AMPE
Ampio Pharmaceuticals, Inc.
Primary endpoint added: Number of Participants With a 50 Percent Decrease in Mean Stool Count — PHASE4
NCT03898856
• Phase 4
MEDIUM
2026-02-12
C
CHCO
CITY HOLDING CO
Enrollment 37→31 (-16%) — NA
NCT05443347
• Na • Enrollment 37→31 (-16%)
MEDIUM
2026-02-12
R
RYTM
RHYTHM PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT06760546
• Phase 3
MEDIUM
2026-02-12
R
RYTM
RHYTHM PHARMACEUTICALS, INC.
Enrollment 20→18 (-10%) — PHASE2
NCT06772597
• Phase 2 • Enrollment 20→18 (-10%)
MEDIUM
2026-02-12
K
KPTI
Karyopharm Therapeutics Inc.
Locations updated — PHASE2
NCT05980806
• Phase 2
MEDIUM
2026-02-12
F
FDMT
4D Molecular Therapeutics, Inc.
Locations updated — PHASE1
NCT05197270
• Phase 1
MEDIUM
2026-02-12
K
KPTI
Karyopharm Therapeutics Inc.
Enrollment 118→58 (-51%) — PHASE2
NCT05980806
• Phase 2 • Enrollment 118→58 (-51%)
MEDIUM
2026-02-12
AMGN
AMGEN INC
Enrollment 100→102 (2%) — PHASE4
NCT06332014
• Phase 4 • Enrollment 100→102 (+2%)
MEDIUM
2026-02-12
M
MRBK
Meridian Corp
Enrollment 50→40 (-20%) — NA
NCT06897618
• Na • Enrollment 50→40 (-20%)
MEDIUM
2026-02-12
O
ONON
On Holding AG
Primary endpoint added: Change in youth firearm violence involvement — NA
NCT06940362
• Na
MEDIUM
2026-02-12
F
FULC
Fulcrum Therapeutics, Inc.
Enrollment 70→45 (-36%) — PHASE1
NCT05169580
• Phase 1 • Enrollment 70→45 (-36%)
MEDIUM
2026-02-12
F
FULC
Fulcrum Therapeutics, Inc.
Locations updated — PHASE1
NCT05169580
• Phase 1
MEDIUM
2026-02-12
A
AARD
Aardvark Therapeutics, Inc.
Locations updated — PHASE3
NCT06828861
• Phase 3
MEDIUM
2026-02-12
Z
ZURA
Zura Bio Ltd
Enrollment 180→225 (25%) — PHASE2
NCT06993610
• Phase 2 • Enrollment 180→225 (+25%)
MEDIUM